(Q44543810)

4 December 2017

title

Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution (English)

1 reference

4 December 2017

0 references

1 reference

ChEBI release 2020-05-28

6

Eric Q Wu

1 reference

4 December 2017

Jie Zhang

3

1 reference

4 December 2017

Dominick Latremouille-Viau

4

1 reference

4 December 2017

Markus von Wartburg

5

1 reference

4 December 2017

Lizheng Shi

7

1 reference

4 December 2017

Gregory S. Sawicki

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21815282

8 December 2024

James E. Signorovitch

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21815282

8 December 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21815282

8 December 2024

publication date

3 August 2011

1 reference

full work available at URL

4 December 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fppul.21521

1 reference

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ppul.21521

8 December 2024

1 reference

8 December 2024

published in

Pediatric Pulmonology

1 reference

4 December 2017

volume

47

1 reference

4 December 2017

issue

1

1 reference

4 December 2017

page(s)

44-52

1 reference

Predictive 5-year survivorship model of cystic fibrosis

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21521

Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21521

Administration of aerosolized antibiotics in cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21521

Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21521

Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21521

A prognostic model for the prediction of survival in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21521

Mortality of cystic fibrosis patients treated with tobramycin solution for inhalation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21521

Models for longitudinal data: a generalized estimating equation approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21521

Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21521

Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21521

Adherence to treatment in children and adolescent patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21521

Case-mix adjustment for evaluation of mortality in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21521

Gender gap in cystic fibrosis mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21521

Estimating effectiveness in an observational study: a case study of dornase alfa in cystic fibrosis. The Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21521

Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21521

Dornase alfa in the treatment of cystic fibrosis in Europe: A report from the Epidemiologic Registry of Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21521

Prevalence and impact of depression in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21521

Factors influencing outcomes in cystic fibrosis: a center-based analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21521

Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis

21 January 2018

3

1 reference

Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis

8 December 2024

4

1 reference

Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group

8 December 2024

6

1 reference

Prediction of Mortality in Patients with Cystic Fibrosis

8 December 2024

9

1 reference

Evaluating the "Leeds criteria" for Pseudomonas aeruginosa infection in a cystic fibrosis centre.

8 December 2024

21

1 reference

Effects of Recombinant Human DNase Therapy on Healthcare use and Costs in Patients with Cystic Fibrosis

8 December 2024

28

1 reference

8 December 2024

Identifiers

DOI

10.1002/PPUL.21521

1 reference

4 December 2017

1 reference